A GIANT can sometimes grow from a midget (not to offend)!Electrome, ActiPatch sales growth, and consumer interest — October 17, 2026
My assessment is that Electrome has made meaningful progress in launching and marketing ActiPatch, but there is not yet enough publicly verified sales data to establish that sales are increasing at the rate needed to make BioElectronics Corporation (OTC: BIEL) sustainably profitable.
There are encouraging signs: the commercial rollout has advanced, the consumer website has been developed, the company is promoting a short educational Pain Check, and the product is available for direct purchase. The key distinction is between building a sales platform and demonstrating actual sales growth.
1. What the latest developments tell us
Commercial launch and manufacturing
Positive development
On June 17, 2026, BioElectronics announced that its distribution and licensing agreement with Electrome had entered the execution phase. The announcement reported receipt of an initial purchase order and commencement of manufacturing for the Electrome platform rollout.
This is evidence of commercial activity, but an initial purchase order does not establish the volume of subsequent reorders or consumer sales.
Consumer-facing Pain Check
Marketing infrastructure live
The ActiPatch website now offers a nine-question, approximately five-minute assessment that gives users pain-location guidance and educational information.
Where to Place ActiPatch
This is a useful way to educate potential buyers and direct interested consumers toward the product. Publicly available information does not disclose how many people start or complete the assessment, or how many then buy.
Direct-to-consumer distribution
Electrome's consumer launch describes three intended channels: online direct sales, healthcare-provider relationships, and retail distribution, with affiliate and creator marketing planned as a subsequent phase.
These channels could broaden the addressable market considerably. The unresolved question is how many are already generating material revenue rather than simply being prepared for launch.
2. Is Electrome actually increasing ActiPatch sales?
The public evidence is encouraging, but it is not yet conclusive.
Indicator What the evidence shows Assessment
Initial Electrome purchase order Reported by BIEL in June 2026 Positive
Manufacturing and fulfillment Manufacturing underway; fulfillment capacity expanded in July Positive operational progress
Consumer e-commerce Product is available for direct purchase Sales channel established
Monthly BIEL sales BIEL's chairman reported an increase in monthly sales across OTC and professional markets in June Positive, but not attributable solely to Electrome
Electrome sales volume No verified unit-sales or monthly revenue figures identified in the sources reviewed Unconfirmed
Repeat orders from Electrome No quantified reorder history identified Unconfirmed
Sources: BIEL's June 30 chairman update and July 21 fulfillment expansion announcement.
An important distinction is that the July announcement described the expanded facility as support for a planned consumer launch and anticipated sales growth. More warehouse space and order-processing capacity are preparations for demand, not proof that the demand has materialized.
My conclusion on sales: I would characterize ActiPatch as being in an early commercial scaling phase. I cannot yet establish that Electrome's sales are growing month over month, or quantify the growth rate.
3. Consumer interest in the Pain Check
ActiPatch Pain Check
Open the live assessment
The nine-question assessment asks where the user experiences pain and provides educational guidance. Its design encourages a potential customer to identify a problem, learn about a possible treatment, and proceed toward a purchase.
Where to Place ActiPatch
My evaluation of the consumer proposition
1. The problem is widespread
Muscle, joint, back, knee, and neck pain affect a large potential customer base. A drug-free wearable that requires no prescription
has a relatively straightforward consumer proposition.
2. The price is accessible for a trial purchase
The current listed price is $39.99 for one device, $77.98 for two, and $113.97 for three. The site also advertises a 30-day money-back guarantee and free shipping through December 31, 2026, for eligible US and Canadian orders.
FDA-Cleared Drug-Free Pain Relief
That pricing may reduce the barrier to trying a drug-free pain-management product.
3. The assessment is not proof of demand
The Pain Check page does not publish visitor counts, completed assessments, purchase conversion rates, or customer acquisition costs. It also states that answers are not saved or transmitted, so the assessment itself does not provide a publicly visible measure of consumer engagement.
What do customer reviews tell us?
The evidence is mixed in quantity, but there are encouraging qualitative signals.
- ActiPatch's own review page: Electrome's page published September 26, 2026, contains personal experiences shared with permission, but states that no customer reviews linked to verified purchases have yet been published in its store review section.
ActiPatch
- Trustpilot: The ActiPatch profile showed 17 reviews and a 4.5/5 TrustScore in the retrieved results, with one review in the preceding 12 months. The comments include reports of pain relief and some negative experiences. These reviews are self-selected and do not establish typical treatment outcomes or current sales volume.
Read Customer Service Reviews of actipatch.com
My interpretation is that there is evidence of genuine consumer interest in the product concept, but the publicly visible review base is too small to demonstrate mass-market adoption. The difference between positive individual experiences and broad commercial demand is particularly important for an OTC medical device.
4. How strong is the opportunity for BIEL?
I would separate the consumer opportunity from the investment opportunity.
My current assessment
Consumer appeal
Promising
The combination of drug-free treatment, wearable convenience, a modest initial purchase price, and a guided educational experience gives Electrome a credible product proposition.
Marketing execution
Progressing
The storefront, product education, and distribution infrastructure are visible. Actual advertising reach and conversion performance remain undisclosed.
Verified sales growth
Unproven
The available announcements establish commercial preparation and an initial order, but do not establish sustained growth in Electrome's consumer sales.
BIEL profitability from Electrome
Uncertain
The financial impact will depend on order volume, the revenue BIEL receives per unit, manufacturing costs, and whether the new business covers its operating expenses.
What I would monitor over the next two quarters
The following indicators would turn the current marketing story into evidence of a commercially successful rollout:
1. Repeat purchase orders: Electrome orders additional inventory in meaningful quantities, rather than relying on its initial order.
2. Quarterly BIEL revenue: Reported revenue rises compared with the previous quarter and the same quarter of the prior year.
3. Gross profit and cash flow: Sales generate sufficient margin and cash to cover manufacturing and operating expenses.
4. Pain Check conversion: Electrome discloses the number of assessment completions and the percentage converting into purchases.
5. Independent consumer feedback: Verified-purchase reviews increase, including enough feedback to assess both positive and negative experiences.
One qualification: the Pain Check is primarily an educational funnel, not necessarily a recurring-revenue product. The device is consumable, so customer acquisition costs, customer referrals, and repeat purchases or purchases for additional pain locations will matter to the economics.
Final verdict
I see a credible opportunity for ActiPatch to gain consumers, but I would not yet treat the Electrome rollout as a proven sales-growth success for BIEL. The next meaningful evidence would be quantified sales and repeat orders, not further announcements about marketing infrastructure.
The single most valuable disclosure from Electrome would be its monthly ActiPatch unit sales from launch onward, accompanied by the average selling price and return rate. From BIEL, I would want to see the corresponding quarterly revenue and gross profit attributable to Electrome.
Those figures would allow a much more defensible estimate of whether the partnership could drive BIEL toward sustained profitability and potentially support a higher share price.
Just a baby ready to grow into a GIANT!
My assessment is that Electrome has made meaningful progress in launching and marketing ActiPatch, but there is not yet enough publicly verified sales data to establish that sales are increasing at the rate needed to make BioElectronics Corporation (OTC: BIEL) sustainably profitable.
There are encouraging signs: the commercial rollout has advanced, the consumer website has been developed, the company is promoting a short educational Pain Check, and the product is available for direct purchase. The key distinction is between building a sales platform and demonstrating actual sales growth.
1. What the latest developments tell us
Commercial launch and manufacturing
Positive development
On June 17, 2026, BioElectronics announced that its distribution and licensing agreement with Electrome had entered the execution phase. The announcement reported receipt of an initial purchase order and commencement of manufacturing for the Electrome platform rollout.
This is evidence of commercial activity, but an initial purchase order does not establish the volume of subsequent reorders or consumer sales.
Consumer-facing Pain Check
Marketing infrastructure live
The ActiPatch website now offers a nine-question, approximately five-minute assessment that gives users pain-location guidance and educational information.
Where to Place ActiPatch
This is a useful way to educate potential buyers and direct interested consumers toward the product. Publicly available information does not disclose how many people start or complete the assessment, or how many then buy.
Direct-to-consumer distribution
Electrome's consumer launch describes three intended channels: online direct sales, healthcare-provider relationships, and retail distribution, with affiliate and creator marketing planned as a subsequent phase.
These channels could broaden the addressable market considerably. The unresolved question is how many are already generating material revenue rather than simply being prepared for launch.
2. Is Electrome actually increasing ActiPatch sales?
The public evidence is encouraging, but it is not yet conclusive.
Indicator What the evidence shows Assessment
Initial Electrome purchase order Reported by BIEL in June 2026 Positive
Manufacturing and fulfillment Manufacturing underway; fulfillment capacity expanded in July Positive operational progress
Consumer e-commerce Product is available for direct purchase Sales channel established
Monthly BIEL sales BIEL's chairman reported an increase in monthly sales across OTC and professional markets in June Positive, but not attributable solely to Electrome
Electrome sales volume No verified unit-sales or monthly revenue figures identified in the sources reviewed Unconfirmed
Repeat orders from Electrome No quantified reorder history identified Unconfirmed
Sources: BIEL's June 30 chairman update and July 21 fulfillment expansion announcement.
An important distinction is that the July announcement described the expanded facility as support for a planned consumer launch and anticipated sales growth. More warehouse space and order-processing capacity are preparations for demand, not proof that the demand has materialized.
My conclusion on sales: I would characterize ActiPatch as being in an early commercial scaling phase. I cannot yet establish that Electrome's sales are growing month over month, or quantify the growth rate.
3. Consumer interest in the Pain Check
ActiPatch Pain Check
Open the live assessment
The nine-question assessment asks where the user experiences pain and provides educational guidance. Its design encourages a potential customer to identify a problem, learn about a possible treatment, and proceed toward a purchase.
Where to Place ActiPatch
My evaluation of the consumer proposition
1. The problem is widespread
Muscle, joint, back, knee, and neck pain affect a large potential customer base. A drug-free wearable that requires no prescription
has a relatively straightforward consumer proposition.
2. The price is accessible for a trial purchase
The current listed price is $39.99 for one device, $77.98 for two, and $113.97 for three. The site also advertises a 30-day money-back guarantee and free shipping through December 31, 2026, for eligible US and Canadian orders.
FDA-Cleared Drug-Free Pain Relief
That pricing may reduce the barrier to trying a drug-free pain-management product.
3. The assessment is not proof of demand
The Pain Check page does not publish visitor counts, completed assessments, purchase conversion rates, or customer acquisition costs. It also states that answers are not saved or transmitted, so the assessment itself does not provide a publicly visible measure of consumer engagement.
What do customer reviews tell us?
The evidence is mixed in quantity, but there are encouraging qualitative signals.
- ActiPatch's own review page: Electrome's page published September 26, 2026, contains personal experiences shared with permission, but states that no customer reviews linked to verified purchases have yet been published in its store review section.
ActiPatch
- Trustpilot: The ActiPatch profile showed 17 reviews and a 4.5/5 TrustScore in the retrieved results, with one review in the preceding 12 months. The comments include reports of pain relief and some negative experiences. These reviews are self-selected and do not establish typical treatment outcomes or current sales volume.
Read Customer Service Reviews of actipatch.com
My interpretation is that there is evidence of genuine consumer interest in the product concept, but the publicly visible review base is too small to demonstrate mass-market adoption. The difference between positive individual experiences and broad commercial demand is particularly important for an OTC medical device.
4. How strong is the opportunity for BIEL?
I would separate the consumer opportunity from the investment opportunity.
My current assessment
Consumer appeal
Promising
The combination of drug-free treatment, wearable convenience, a modest initial purchase price, and a guided educational experience gives Electrome a credible product proposition.
Marketing execution
Progressing
The storefront, product education, and distribution infrastructure are visible. Actual advertising reach and conversion performance remain undisclosed.
Verified sales growth
Unproven
The available announcements establish commercial preparation and an initial order, but do not establish sustained growth in Electrome's consumer sales.
BIEL profitability from Electrome
Uncertain
The financial impact will depend on order volume, the revenue BIEL receives per unit, manufacturing costs, and whether the new business covers its operating expenses.
What I would monitor over the next two quarters
The following indicators would turn the current marketing story into evidence of a commercially successful rollout:
1. Repeat purchase orders: Electrome orders additional inventory in meaningful quantities, rather than relying on its initial order.
2. Quarterly BIEL revenue: Reported revenue rises compared with the previous quarter and the same quarter of the prior year.
3. Gross profit and cash flow: Sales generate sufficient margin and cash to cover manufacturing and operating expenses.
4. Pain Check conversion: Electrome discloses the number of assessment completions and the percentage converting into purchases.
5. Independent consumer feedback: Verified-purchase reviews increase, including enough feedback to assess both positive and negative experiences.
One qualification: the Pain Check is primarily an educational funnel, not necessarily a recurring-revenue product. The device is consumable, so customer acquisition costs, customer referrals, and repeat purchases or purchases for additional pain locations will matter to the economics.
Final verdict
I see a credible opportunity for ActiPatch to gain consumers, but I would not yet treat the Electrome rollout as a proven sales-growth success for BIEL. The next meaningful evidence would be quantified sales and repeat orders, not further announcements about marketing infrastructure.
The single most valuable disclosure from Electrome would be its monthly ActiPatch unit sales from launch onward, accompanied by the average selling price and return rate. From BIEL, I would want to see the corresponding quarterly revenue and gross profit attributable to Electrome.
Those figures would allow a much more defensible estimate of whether the partnership could drive BIEL toward sustained profitability and potentially support a higher share price.
Just a baby ready to grow into a GIANT!
1
